Table 1.
Clinical characteristics of control subjects and obese patients with type 2 diabetes mellitus.
| Parameters | Control Subjects | Obese Patients with Type 2 Diabetes Mellitus | |
|---|---|---|---|
| Before the Implementation of Insulin Therapy | After a 6-Month Insulin Treatment | ||
| Gender Female/Male (n) | 20 (7F/13 M) | 42 (19 F/23 M) | 42 (19 F/23 M) |
| Age (yr) | 54.81 ± 8.64 | 60.98 ± 5.63 | 61.76 ± 6.63 |
| Disease duration (yr) | – | 13.05 ± 6.49 | 13.65 ± 6.49 |
| BMI (kg/m2) | 29.63 ± 5.40 | 33.09 ± 4.09 | 33.03 ± 4.14 |
| WHR (cm2) | 0.95 ± 0.07 | 1.01 ± 0.05 | 1.00 ± 0.06 |
| Glucose (mg/dL) | 91.38 ± 6.86 | 134.12 ± 30.03 a | 136.64 ± 25.53 |
| HbA1c (%) | 5.19 ± 0.34 | 7.30 ± 1.10 a | 7.67 ± 1.03 b |
| Triglycerides (mg/dL) | 168.95 ± 59.46 | 163.63 ± 88.11 | 179.15 ± 69.33 b |
| Cholesterol (mg/dL) | 193.31 ± 34.77 | 183.75 ± 55.08 | 186.93 ± 30.01 |
| HDL (mg/dL) | 46.99 ± 8.90 | 50.92 ± 16.62 | 49.01 ± 14.59 |
| LDL (mg/dL) | 116.03 ± 29.12 | 107.49 ± 36.70 | 100.79 ± 28.17 |
| Creatinine (mg/dL) | 0.84 ± 0.09 | 0.87 ± 0.23 | 0.92 ± 0.35 |
| Uric acid (mg/dL) | 5.15 ± 0.79 | 5.53 ± 1.56 | 7.17 ± 1.44 b |
| ALT (U/L) | 29.75 ± 8.02 | 30.92 ± 16.12 | 34.12 ± 14.36 |
| TSH (mU/L) | 2.43 ± 0.33 | 1.88 ± 1.79 | 1.45 ± 0.43 |
| CRP (mg/L) | 0.85 ± 0.58 | 0.69 ± 0.51 | 0.23 ± 0.15 |
Values given as mean ± SD; F, female; M, male; BMI, body mass index; WHR, waist–hip ratio; HbA1c, glycated haemoglobin; HDL, high density lipoprotein; LDL, high density lipoprotein; ALT, alanine aminotransferase; TSH, thyroid stimulating hormone CRP, C-reactive protein; a p < 0.0001 compared with controls; b p < 0.05 compared with obese patients with T2DM before insulin therapy.